1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Real-time Estimate Cboe BZX  -  08:30 2022-08-15 am EDT
42.02 USD   +1.31%
08:19aNovavax seeks U.S. authorization for COVID vaccine booster
RE
08:11aNovavax seeks U.S. authorization for COVID vaccine booster
RE
08:01aNovavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EMA's CHMP Approves New Manufacturing Site For Active Substance Of COVID-19 Vaccine Nuvaxovid

07/05/2022 | 04:41am EDT

July 5 (Reuters) - European Medicines Agency:

* EMA: EMA'S CHMP APPROVED A NEW MANUFACTURING SITE FOR THE ACTIVE SUBSTANCE OF COVID-19 VACCINE NUVAXOVID: 05/07/2022 Further company coverage:


© Reuters 2022
All news about NOVAVAX, INC.
08:19aNovavax seeks U.S. authorization for COVID vaccine booster
RE
08:11aNovavax seeks U.S. authorization for COVID vaccine booster
RE
08:01aNovavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax..
PR
07:47aNovavax and partner SK bioscience will provide the first protein-based COVID-19 vaccine..
AQ
08/12Novavax COVID-19 Vaccine Receives Approval in South Korea for Use in Adolescents
MT
08/12Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescent..
PR
08/12Novavax Vaccine Approved for Adolescents in South Korea
DJ
08/11Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum
PR
08/10Novavax Gets Thai Regulator's Emergency Use Authorization for COVID-19 Vaccine for Ages..
MT
08/10B. Riley Securities Lowers Novavax's Price Target to $126 from $171 After Lower-than-Ex..
MT
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 2 379 M - -
Net income 2022 319 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 10,5x
Yield 2022 -
Capitalization 3 244 M 3 244 M -
EV / Sales 2022 0,31x
EV / Sales 2023 -0,04x
Nbr of Employees 1 541
Free-Float 98,8%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 41,47 $
Average target price 125,83 $
Spread / Average Target 203%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-71.01%3 244
MODERNA, INC.-32.60%66 966
IQVIA HOLDINGS INC.-12.88%45 846
LONZA GROUP AG-25.13%44 851
SEAGEN INC.10.05%31 380
ALNYLAM PHARMACEUTICALS, INC.37.90%28 068